29 OCT 2003




Fig. 1



TNF-α in sera / 1h after injection
pg/ml
200
150
100
50
0
-
+ pR 60
+ CpG 1668
+ I-ODN 1
+ I-ODN 2
+ I-ODN 3
+ pR 60 + CpG 1668
+ pR 60 + I-ODN 1
+ pR 60 + I-ODN 2
+ pR 60 + I-ODN 3
injection of OVA257-264

Fig. 2




Fig. 3 injection of $OVA_{257-264}$



TNF-α/IL-6 in sera / 1h after injection
TNF-a
IL-6
pg/ml
200
150
100
50
0
-
+ pR 60
+ CpG 1668
+ GpC
+ I-ODN 9
+ I-ODN 10
+ pR 60 + CpG 1668
+ pR 60 + GpC
+ pR 60 + I-ODN 9
+ pR 60 + I-ODN 10
injection of OVA257-264

Fig. 4



TRP2 181-188
OVA 257-264
pR
IFN-γ producing cells / 10⁶ LN cells
1500
1000
500
0
-
+ pR 60
+ CpG 1668
+ wdi
+ widin
+ wid
+ widid
+ pR 60 + CpG 1668
+ pR 60 + wdi
+ pR 60 + widin
+ pR 60 + wid
+ pR 60 + widid
injection of TRP-2181-188

Fig. 5



TRP-2
OVA257-265
IFN-g+ spots/1x10^6 LN cells
900
800
700
600
500
400
300
200
100
0
-
+ pR (100µg)
+ CpG 1668 (5nMol)
+ I-ODN 2 (5nMol)
+ pR (100µg) + CpG 1668 (5nMol)
+ pR (100µg) + I-ODN 2 (5nMol)
Injection of TRP-2 181-188 (100µg)

Fig. 6



TNF-α
TNF-a (pg / m
250
200
150
100
50
0
-
pR
CpG 1668
I-ODN 2
pR + CpG 1668
pR + I-ODN 2
injection of TRP-2 181-188 +
IL-6
IL-6 (pg/ml)
90
80
70
60
50
40
30
20
10
0
pR (100µg)
CpG 1668 (5nMol)
I-ODN 2 (5nMol)
CpG 1668 (5nMol) + pR (100µg)
I-ODN 2 (5nMol)+ pR (100µg)
Injection of TRP-2 181-188 (100µg) +

Fig. 7




TRP-2 181-188
OVA257-265
IFN-g+ spots / 1x10^6 LN cells
700
600
500
400
300
200
100
0
-
+ pR (100µg)
+ CpG 1668 (5nMol)
+ ODN 17 (10nMol)
+ pR (100µg) + CpG 1668 (5nMol)
+ pR (100µg) + ODN 17 (10nMol)
Injection of TRP-2 181-188 (100µg) +


Fig. 8

Fig. 9

A)


OVA-IgG2a
200
150
100
50
0
Ab titer
day 24
day 115
-
pR
oligo-dIC26
pR+oligo-dIC26
injection of OVA +

B)


OVA-IgG1
1000
800
600
400
200
0
Ab titer
day 24
day 115
-
pR
oligo-dIC26
pR+oligo-dIC26
injection of OVA +